{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/eczema-atopic/management/mild-eczema/","result":{"pageContext":{"chapter":{"id":"0cccd619-b2de-56ab-aa4b-8335f760ada1","slug":"mild-eczema","fullItemName":"Scenario: Mild eczema","depth":2,"htmlHeader":"<!-- begin field 21faad9f-a719-431f-88e8-1c0ee1b28c8a --><h2>Scenario: Mild eczema</h2><!-- end field 21faad9f-a719-431f-88e8-1c0ee1b28c8a -->","summary":"Covers the management of a person with areas of dry skin and/or infrequent itching (with or without small areas of redness).","htmlStringContent":"<!-- begin item 6fa17576-e540-45d5-9188-8d229beb5eb4 --><!-- begin field 04a46f1a-46dd-4f24-a8c9-acbd00858151 --><p>From age 1 month onwards.</p><!-- end field 04a46f1a-46dd-4f24-a8c9-acbd00858151 --><!-- end item 6fa17576-e540-45d5-9188-8d229beb5eb4 -->","topic":{"id":"63a4e43b-49fe-563e-ac98-e9b0859c592c","topicId":"68307f26-e94a-48b4-9595-fadcb2fdee8a","topicName":"Eczema - atopic","slug":"eczema-atopic","lastRevised":"Last revised in January 2021","chapters":[{"id":"168b58b7-fdd4-50a2-b9ec-27d907398222","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"8bb5c02b-0104-5f27-98ba-1b53ded774ba","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"98e1b8e0-503c-57ac-9ef2-caacc212e152","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"d176eafc-9dcd-5f10-84a7-1d302a858223","slug":"changes","fullItemName":"Changes"},{"id":"6d4019a1-b2bb-54e9-895a-a2edc7b87429","slug":"update","fullItemName":"Update"}]},{"id":"9c4faee5-cf0b-515b-bc4a-a31602a94782","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"538ef47b-cfe7-5fca-beb8-19aa8e5bf9c1","slug":"goals","fullItemName":"Goals"},{"id":"a0383042-27f4-54a3-a484-e3a5a53f6625","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"2c77a3c3-9932-5d7d-91b5-418e832f5312","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"8baad0b5-8401-5866-829c-d480e381e783","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"a521d8b1-827a-5781-ad45-f3791b4e1bd1","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"8cf8749d-acfe-5549-ab78-d5cf32ea5fbf","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"a7eb5aa7-360a-51dc-8e4c-daad28913df0","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"5a643f13-59c4-52ad-b851-dc4e8a73f354","slug":"definition","fullItemName":"Definition"},{"id":"ebbfabd2-e0e3-5987-aa33-c3fa2ba187da","slug":"causes","fullItemName":"Causes"},{"id":"e7a40326-66ce-59e3-bdcb-86b1b0b611ea","slug":"prevalence","fullItemName":"Prevalence"},{"id":"9944d177-a960-52fd-8b8c-6d34afadddcb","slug":"complications","fullItemName":"Complications"},{"id":"01750b87-b8f0-5ec7-bda0-23ae3f563218","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"9692db09-38c6-5f1b-bc48-0e6606729c0c","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"4ff05ba7-7a47-5830-a6d0-a3c723344964","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"b23630ce-69bb-56e8-9fae-e120331f815f","slug":"identifying-trigger-factors","fullItemName":"Identifying trigger factors"},{"id":"9cf9065e-b2c1-545d-a347-325c756ba267","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"084c2672-a546-5c1a-925f-c2b2579ea662","fullItemName":"Management","slug":"management","subChapters":[{"id":"d5478272-79bf-561d-86b2-264a10149cc9","slug":"assessment","fullItemName":"Scenario: Assessment"},{"id":"0cccd619-b2de-56ab-aa4b-8335f760ada1","slug":"mild-eczema","fullItemName":"Scenario: Mild eczema"},{"id":"fd373e1c-c93c-5467-8984-3ffb57f4db96","slug":"moderate-eczema","fullItemName":"Scenario: Moderate eczema"},{"id":"60c5ed4a-3cf7-5f16-a959-9ebb082384a8","slug":"severe-eczema","fullItemName":"Scenario: Severe eczema"},{"id":"b127c625-6749-5a79-839f-88edee29b634","slug":"infected-eczema","fullItemName":"Scenario: Infected eczema"},{"id":"be3c1aab-3810-578d-a12d-7fa8a3bda3af","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"7a62824e-ab17-5ec8-b4eb-832ae0ea1ed2","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"a6a60e24-add6-5b81-96c6-7556a07ce5ef","slug":"stepped-approach-to-treatment","fullItemName":"Stepped approach to treatment"},{"id":"32834cc1-317c-5325-a3c6-54b2bfa53088","slug":"emollients","fullItemName":"Emollients"},{"id":"93edf0ec-6483-5c88-a432-bb01d2b3b606","slug":"topical-corticosteroids","fullItemName":"Topical corticosteroids"},{"id":"33241bf6-534a-5809-8c00-641507b16a6b","slug":"oral-antihistamines","fullItemName":"Oral antihistamines"},{"id":"f30bf02b-a3bb-581a-bc1f-853575c7f434","slug":"oral-corticosteroids","fullItemName":"Oral corticosteroids"},{"id":"6432a48a-76f3-534e-a4c1-8ec000fe6d58","slug":"oral-antibiotics","fullItemName":"Oral antibiotics"},{"id":"24b6d226-2567-5496-8557-dbfabde4e855","slug":"topical-antibiotics-antiseptics","fullItemName":"Topical antibiotics and antiseptics"}]},{"id":"a24fe8c8-994b-5b5d-a725-12ab08a2b0e6","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"aaad8885-ddf1-52ea-9dbb-520435cbe52b","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"2a17d479-605d-53c6-aac4-d2dee258e56e","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"134abf73-7ae8-51e1-9f52-342c5379bcb0","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"5fa037f5-1815-5c07-ad67-d491a2c34652","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"4a76468f-46d6-51a1-9527-915b5596d2ad","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"15077c82-8b21-52ca-88cb-b5b956cd2ae6","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"cc9ef2ce-7217-5486-b5fe-23241bc45da4","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"084c2672-a546-5c1a-925f-c2b2579ea662","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"39c2f2aa-24b5-5a70-b246-ce53c2b261bc","slug":"management","fullItemName":"Management","depth":3,"htmlHeader":"<!-- begin field a45a072b-7590-4750-9693-a7130125bcb3 --><h3>How should I manage a person with mild eczema?      </h3><!-- end field a45a072b-7590-4750-9693-a7130125bcb3 -->","summary":null,"htmlStringContent":"<!-- begin item ea3a6dfa-0196-48d7-a813-a7130125ba2a --><!-- begin field 823d3674-50f7-4087-8ec3-a7130125bcb3 --><p><strong>If a person presents with <a class=\"topic-reference internal-reference\" href=\"/topics/eczema-atopic/management/assessment/#assessing-severity-of-atopic-eczema\">mild eczema</a> (or an acute flare of mild eczema):</strong></p><ul><li><strong>Prescribe appropriate treatment.</strong><ul><li>Prescribe generous amounts of emollients, and advise frequent and liberal use.</li><li>Consider prescribing a mild topical corticosteroid (such as hydrocortisone 1%) for areas of red skin. Treatment should be continued for 48 hours after the flare has been controlled.</li><li>See the prescribing information sections on <a class=\"topic-reference internal-reference\" href=\"/topics/eczema-atopic/prescribing-information/emollients/\">Emollients</a> and <a class=\"topic-reference internal-reference\" href=\"/topics/eczema-atopic/prescribing-information/topical-corticosteroids/\">Topical corticosteroids</a> for more information on emollients and topical corticosteroids, including available products and usage instructions.</li></ul></li><li><strong>Give appropriate information and advice, </strong>including general information on atopic eczema, measures to maintain the skin and reduce the risk of flares, self-care advice, and information on treatments not recommended. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/eczema-atopic/management/mild-eczema/#additional-information-advice\">Additional information and advice</a> for more information.</li><li><strong>Active follow up is rarely required for mild eczema, unless the person or carer requests it.</strong><ul><li>For people with persisting eczema, consider annual review of emollient use to ensure optimal usage.</li></ul></li><li><strong>Refer for a routine dermatology appointment if:</strong><ul><li>The diagnosis is, or has become, uncertain.</li><li>Current management has not controlled eczema satisfactorily (for example the person is having one to two flares per month), or the person is reacting adversely to many emollients.</li><li>Facial eczema has not responded to appropriate treatment.</li><li>There is recurrent secondary infection.</li></ul></li><li><strong>Refer to a clinical psychologist,</strong> people whose eczema is controlled but whose <a class=\"topic-reference internal-reference\" href=\"/topics/eczema-atopic/management/assessment/#assessing-psychological-impact\">quality of life and psychological well-being</a> have not improved (this may not be directly related to the severity of the eczema).</li></ul><!-- end field 823d3674-50f7-4087-8ec3-a7130125bcb3 --><!-- end item ea3a6dfa-0196-48d7-a813-a7130125ba2a -->","subChapters":[{"id":"c6812120-b62a-56ba-a094-4239cb9b5aab","slug":"basis-for-recommendation-725","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 19225989-ba96-4ed6-8acb-a7130125bcb3 --><h4>Basis for recommendation</h4><!-- end field 19225989-ba96-4ed6-8acb-a7130125bcb3 -->","summary":null,"htmlStringContent":"<!-- begin item 7252cf15-59a1-4c24-a1a1-a7130125bcb3 --><!-- begin field 87cfab5f-589b-466d-822a-a7130125bcb3 --><p>These recommendations are largely based on expert opinion in the National Institute for Health and Care Excellence (NICE) guideline <em>Atopic eczema in under 12s: diagnosis and management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">NICE, 2007a</a>].<em> </em>NICE reviewed this guideline in July 2016 and found no new evidence to warrant a change in recommendations. CKS has extrapolated the recommendations to include the management of older children and adults. </p><p>These recommendations are also in line with those in <em>Management of atopic eczema in primary care </em>published by the Scottish Intercollegiate Guideline Network (SIGN) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">SIGN, 2011</a>], <em>Caring for children and young people with atopic eczema: guidance for nurses</em> published by the Royal College of Nursing (RCN) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">RCN, 2013</a>], <em>Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies </em>published by the<em> </em>American Academy of Dermatology (AAD) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Eichenfield, 2014b</a>], <em>Atopic eczema</em> published by the Primary Care Dermatology Society (PCDS) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Primary Care Dermatology Society, 2016</a>], <em>S2k guideline on diagnosis and treatment of atopic dermatitis - short version </em>(a German guideline<em> </em>supported financially by the<em> </em>German Dermatology Society [DDG]) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Werfel, 2016</a>], the <em>ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients </em>published by the European Task Force on Atopic Dermatitis (ETFAD) and European Academy of Dermatology and Venerology (EADV) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Wollenberg, 2016</a>], and in review articles on atopic eczema [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Arkwright, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Baron, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Tollefson, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Eichenfield, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Lyons, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Ng, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">BMJ, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Stein, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Strathie, 2016</a>].</p><h5>Prescribing appropriate treatment</h5><ul><li>NICE recommends a stepped approach for managing atopic eczema. This means that treatment should be tailored to the severity of the eczema, and stepped up or down according to the severity of symptoms [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">NICE, 2007a</a>].</li><li><strong>Emollients</strong> are almost universally recommended as first-line treatment for atopic eczema, and experts advise that they should form the basis of management and should always be used, even when the skin is clear [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">NICE, 2007a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">SIGN, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Baron, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">RCN, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Eichenfield, 2014b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Eichenfield, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Lyons, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Ng, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">BMJ, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Primary Care Dermatology Society, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Strathie, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Wollenberg, 2016</a>].<ul><li>A Cochrane systematic review of 77 studies (n = 6603, mean age = 18.6 years, mean duration = 6.7 weeks) assessed the effects of moisturisers for eczema [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">van Zuuren, 2017</a>].   <ul><li>The evidence suggested that most moisturisers showed some beneficial effects in prolonging time to flare, reducing the number of flares, and reducing the amount of topical corticosteroids needed to achieve similar reductions in eczema severity, producing better results when used with active treatment. However, there was no evidence that one moisturiser is better than another. </li><li>Adverse events reporting was limited (smarting, stinging, pruritus, erythema, and folliculitis).</li></ul></li></ul></li><li><strong>Topical corticosteroids</strong> are the most effective treatments to address the inflammatory component of atopic eczema [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Eichenfield, 2014b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Lyons, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Primary Care Dermatology Society, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Wollenberg, 2016</a>], and there is reasonable evidence of benefit for their use [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Nankervis, 2016</a>]. <ul><li>The potency of the topical steroid should be tailored to the severity of the eczema and the area of the skin being treated [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">NICE, 2007a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Lyons, 2015</a>].</li></ul></li></ul><h5>Giving appropriate information and advice</h5><ul><li>See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/eczema-atopic/management/mild-eczema/#additional-information-advice\">Additional information and advice</a> for more information.</li></ul><h5>Active follow up not required</h5><ul><li>These recommendations are consistent with the NICE guideline, although the specific recommendations for follow up are incomplete. Where this is the case, CKS offers guidance based on pragmatism and good clinical practice.</li><li>NICE states that the repeat prescribing of emollients over long periods without review should be discouraged, and annual reviews should be carried out [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">NICE, 2007a</a>]. However, this may not be necessary in people with small areas of mild eczema that require minimal intervention.</li></ul><h5>Referral</h5><ul><li>The NICE Guideline Development Group (GDG) could not find any clinical evidence or evidence on cost-effectiveness in relation to referral and treatment outcomes for eczema. The GDG therefore based these recommendations on referral advice from other guidance and on the GDG's collective experience.</li><li>The recommendations are also in line with recommendations in other guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Eichenfield, 2014a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Primary Care Dermatology Society, 2016</a>] and review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Arkwright, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Tollefson, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Strathie, 2016</a>] on atopic eczema.</li></ul><!-- end field 87cfab5f-589b-466d-822a-a7130125bcb3 --><!-- end item 7252cf15-59a1-4c24-a1a1-a7130125bcb3 -->","subChapters":[]}]},{"id":"e9582d41-aa97-5107-a8b9-86af3569fbfe","slug":"additional-information-advice","fullItemName":"Additional information and advice","depth":3,"htmlHeader":"<!-- begin field ea39423c-ed39-4b29-9331-6ce922c78498 --><h3>What information and self-care advice on eczema should I give?</h3><!-- end field ea39423c-ed39-4b29-9331-6ce922c78498 -->","summary":null,"htmlStringContent":"<!-- begin item 1b0ba71a-4993-4c39-8951-df074b1de7fc --><!-- begin field cafcf0df-545a-4611-9636-4bf548146a1a --><ul><li><strong>Provide information on atopic eczema.</strong><ul><li>Explain that eczema is a chronic illness characterized by flares, which can usually be controlled with appropriate treatment.</li><li>Provide information on recognizing:<ul><li>The early or prodromal signs and symptoms of a flare. Should this occur, advise immediate and aggressive treatment using an agreed stepped-care plan.</li><li>The <a class=\"topic-reference internal-reference\" href=\"/topics/eczema-atopic/background-information/complications/\">symptoms and signs</a> of eczema herpeticum, which is a medical emergency.</li><li>The <a class=\"topic-reference internal-reference\" href=\"/topics/eczema-atopic/management/infected-eczema/#management\">symptoms and signs</a> of infected eczema. </li></ul></li><li><strong>In children, </strong>inform parents/carers that:<ul><li>Eczema often improves with time. However, not all children will grow out of it, and it may get worse in teenage or adult life.</li><li>Children with atopic eczema can often develop asthma and/or allergic rhinitis and that sometimes food allergy is associated with atopic eczema, especially in very young children.</li></ul></li></ul></li><li><strong>P</strong><strong>rovide instructions on the <a class=\"topic-reference internal-reference\" href=\"/topics/eczema-atopic/prescribing-information/emollients/#usage-instructions\">correct use of emollients</a>, with clear demonstrations where appropriate. </strong>Also address any concerns regarding <a class=\"topic-reference internal-reference\" href=\"/topics/eczema-atopic/prescribing-information/topical-corticosteroids/#prescribing-issues\">adverse effects of topical corticosteroids</a>, if prescribed.</li><li><strong>Give advice on measures to maintain the skin and reduce the risk of flares.</strong><ul><li>Encourage the frequent and liberal use of emollients, even during periods where the skin is clear.</li><li>Advise that where possible, they should avoid <a class=\"topic-reference internal-reference\" href=\"/topics/eczema-atopic/background-information/causes/\">trigger factors</a> known to exacerbate eczema, such as certain clothing (they should avoid wearing synthetic fibres), soaps or detergents (they should use emollient substitutes), animals, and heat (they should keep rooms cool).<ul><li>House-dust mite avoidance strategies are generally not recommended as they are time consuming and of limited benefit.</li></ul></li><li>Advise that they should avoid scratching the eczema (if possible), and simply rub the area with their fingers to alleviate itch. Nails should be kept short, and anti-scratch mittens should be used in babies with eczema.</li></ul></li><li><strong>Also advise the person and/or their parents/carer that:</strong><ul><li>They should not alter their diet unless under specialist advice.</li><li>Complementary therapies are not recommended for the management of atopic eczema; a healthcare professional should be informed if these are used. Also advise that:<ul><li>Treatments such as homeopathic remedies, herbal medicine, massage, and food supplements (such as evening primrose oil) have not been adequately assessed in clinical trials.</li><li>All therapies that claim effectiveness (including natural remedies) may also have adverse effects.</li><li>Chinese herbal medicines have been associated with life-threatening adverse effects and have in some cases been contaminated with corticosteroids.</li><li>If they insist on using complementary therapies, they should continue using the emollients frequently and liberally, even when the skin is clear.</li></ul></li></ul></li><li><strong>Provide patient information leaflets and information on eczema support groups. </strong><ul><li>For example:<ul><li>The British Association of Dermatologists (BAD) has produced an information leaflet on <a href=\"http://www.bad.org.uk/shared/get-file.ashx?id=69&itemtype=document.\" data-hyperlink-id=\"dec64cd3-419a-4012-b0b9-a8f7014dc920\">Atopic Eczema</a>.</li><li>The National Eczema Society has <a href=\"http://www.eczema.org/factsheets\" data-hyperlink-id=\"c1a62ad6-9a31-427f-905f-a8f7014dc92d\">various factsheets</a> on eczema and treatments available on their website (<a href=\"http://www.eczema.org/\" data-hyperlink-id=\"19b53b08-24d2-4eb9-b79c-a8f7014dcc7d\">www.eczema.org</a>).</li></ul></li><li>Where appropriate, advise on the <a href=\"https://apps.nhsbsa.nhs.uk/ppcwebsales/patient.do\" data-hyperlink-id=\"1d98c678-226d-4ca4-9d00-a8f7014dcdb7\">NHS pre-payment certificate</a> (for people who pay prescription charges).</li></ul></li></ul><!-- end field cafcf0df-545a-4611-9636-4bf548146a1a --><!-- end item 1b0ba71a-4993-4c39-8951-df074b1de7fc -->","subChapters":[{"id":"5064374e-0425-50ef-911d-287cd87aec53","slug":"basis-for-recommendation-ad8","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 68da70b1-3994-4961-aea7-5b293a200a7f --><h4>Basis for recommendation</h4><!-- end field 68da70b1-3994-4961-aea7-5b293a200a7f -->","summary":null,"htmlStringContent":"<!-- begin item ad84d93c-ed02-4e97-b8ee-b57c068ea00a --><!-- begin field 6d18e225-876f-48ac-bddd-1303df537628 --><p>These recommendations are largely based on expert opinion in the National Institute for Health and Care Excellence (NICE) guideline <em>Atopic eczema in under 12s: diagnosis and management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">NICE, 2007a</a>].<em> </em>NICE reviewed this guideline in July 2016 and found no new evidence to warrant a change in recommendations. CKS has extrapolated the recommendations to include the management of older children and adults. </p><p>These recommendations are also in line with those in <em>Caring for children and young people with atopic eczema: guidance for nurses</em> published by the Royal College of Nursing (RCN) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">RCN, 2013</a>], <em>Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies </em>published by the<em> </em>American Academy of Dermatology (AAD) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Eichenfield, 2014b</a>], <em>Atopic eczema</em> published by the Primary Care Dermatology Society (PCDS) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Primary Care Dermatology Society, 2016</a>], <em>S2k guideline on diagnosis and treatment of atopic dermatitis - short version </em>(a German guideline<em> </em>supported financially by the<em> </em>German Dermatology Society [DDG]) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Werfel, 2016</a>], the <em>ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients </em>published by the European Task Force on Atopic Dermatitis (ETFAD) and European Academy of Dermatology and Venerology (EADV) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Wollenberg, 2016</a>], and in review articles on atopic eczema [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Buddenkotte et al, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Baron, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Arkwright, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Eichenfield, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Lyons, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Ng, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">BMJ, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Strathie, 2016</a>]. </p><h5>Providing information on atopic eczema</h5><ul><li>Experts advise that:<ul><li>Providing information on the nature of atopic eczema, a comprehensive skin care plan, and access to good quality information and support is essential to allow families manage atopic eczema [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">NICE, 2007a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Baron, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Arkwright, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">RCN, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Eichenfield, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Lyons, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Werfel, 2016</a>].</li><li>The fear of adverse effects of topical corticosteroids should be recognized and addressed in order to improve adherence and avoid undertreatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Eichenfield, 2014b</a>].</li></ul></li></ul><h5>Advice on measures to maintain the skin and reduce flares</h5><ul><li>Emollients are the first-line treatments for both acute flares of eczema and during remission [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">RCN, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Eichenfield, 2014b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Ng, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Primary Care Dermatology Society, 2016</a>].</li><li>NICE states that treating dry skin (an early sign of a flare) with an emollient may prevent the flare worsening [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">NICE, 2007a</a>].<ul><li>Scratching is thought to be a major component of flare progression, as it physically damages the skin and can delay healing or facilitate infection. Emollients are believed to ease itching and thus may have a role in breaking the itch-scratch cycle [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Grimalt et al, 2007</a>].</li></ul></li><li>A Cochrane systematic review of 77 studies (n = 6603, mean age = 18.6 years, mean duration = 6.7 weeks) assessed the effects of moisturisers for eczema [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">van Zuuren, 2017</a>]. The evidence suggested that most moisturisers showed some beneficial effects in prolonging time to flare, reducing the number of flares, and reducing the amount of topical corticosteroids needed to achieve similar reductions in eczema severity, producing better results when used with active treatment. However, there was no evidence that one moisturiser is better than another. </li></ul><h5>Advice on avoiding triggers</h5><ul><li>Avoiding scratching — the benefit of the short-term relief by scratching the skin is counteracted by a simultaneous damage of the epidermis, leading to increased transepidermal water loss and drying, which in turn results in a cycle of more itching and more scratching [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Buddenkotte et al, 2010</a>].</li><li>House-dust mite avoidance — NICE does not recommend house-dust mite elimination strategies for managing atopic eczema [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">NICE, 2007a</a>]. Although people with atopic eczema are often sensitized to house dust mites [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Eichenfield, 2014a</a>], there is no strong evidence that dust mite avoidance strategies are effective in treating or preventing atopic eczema:<ul><li>A systematic review and meta-analysis (n = 3040) assessed dust mite avoidance measures for the primary prevention of atopic dermatitis and found that they provided no benefit in the prevention of atopic dermatitis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Bremmer, 2015</a>].</li><li>A Cochrane systematic review (search date: August 2014) assessed the effects of house dust mite reduction and avoidance measures for the treatment of atopic eczema and was unable to determine clear implications to inform clinical practice, due to the low-quality evidence available [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Nankervis, 2015</a>].</li></ul></li><li>Irritants, temperature, humidity, pet removal, and stress — NICE found no evidence regarding avoidance of these triggers. However, experts recommend that if these triggers exacerbate eczema, they should be avoided, where possible [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">RCN, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">BAD, 2017</a>].</li><li>Dietary modification:<ul><li>Evidence from a Cochrane systematic review (search date: March 2006) suggests that there is no benefit from milk and egg-free exclusion diets in people who do not have a known allergy to specific foods [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Bath-Hextall et al, 2008</a>].</li><li>Expert opinion in the NICE guideline <em>Food allergy in children and young people. Diagnosis and assessment of food allergy in children and young people in primary care and community settings</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">NICE, 2011b</a>] is that if a food allergy is suspected, a healthcare professional with the appropriate competencies should take an allergy-focused clinical history tailored to the presenting symptoms and age of the child or young person. For more information, see the <a href=\"https://www.nice.org.uk/guidance/cg116/evidence/full-guideline-136470061\" data-hyperlink-id=\"b99d283c-c722-4de1-92cd-a8f701553d29\">full NICE guideline</a>.</li><li>Expert opinion in guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">RCN, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Werfel, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Wollenberg, 2016</a>] and review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Lyons, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Strathie, 2016</a>] on atopic eczema is that any dietary exclusion or elimination diets should be implemented and monitored by a specialist.</li><li>There is limited evidence to recommend the use of few-food diets, elemental diets, probiotic supplements, sodium cromoglicate, dietary exclusion in breastfeeding women [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">NICE, 2007b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Lloyd-Lavery, 2016</a>], or dietary supplements with zinc, essential fatty acids, or vitamin B<sub>6 </sub>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Bath-Hextall and Williams, 2007</a>] for the management of atopic eczema.</li></ul></li></ul><h5>Treatments not recommended</h5><ul><li>There is insufficient evidence to recommend complementary therapies (homeopathy, herbal medicine, massage, and food supplements) in the management of atopic eczema [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">RCN, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">NICE, 2007b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Nankervis, 2016</a>].</li><li>Limited evidence identified by CKS does not support the use of Chinese herbal medicine [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Gu, 2013</a>], oral evening primrose oil [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Bamford, 2013</a>], or borage oil [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Bamford, 2013</a>] for the management of atopic eczema. </li><li>The Medicines and Healthcare products Regulatory Agency (MHRA) warns that the phrases 'natural', 'herbal', and 'derived from plants' do not necessarily mean that the product is 'safe'. Herbal medicines, like other medicines, can have adverse effects. They can also interact with other medicines, resulting in reduced or enhanced effects of the other medicines. For further information, see <a href=\"http://www.mhra.gov.uk/Safetyinformation/Generalsafetyinformationandadvice/Herbalmedicines/Usingherbalmedicinessafely/index.htm\" data-hyperlink-id=\"ae3b46a0-7ba1-41ed-a62f-a8f701553d82\">www.mhra.gov.uk/safetyinformation</a> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">MHRA, 2012</a>].</li></ul><!-- end field 6d18e225-876f-48ac-bddd-1303df537628 --><!-- end item ad84d93c-ed02-4e97-b8ee-b57c068ea00a -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}